Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.23.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 180,571 $ 172,567
Short-term available-for-sale investments 23,739 74,462
Accounts receivable, less allowance for doubtful accounts of $4,738 and $2,568, respectively 218,468 194,548
Inventories 171,638 141,123
Other current assets 27,066 22,856
Total current assets 621,482 605,556
Property and equipment, net 226,200 223,242
Right of use asset 98,326 65,556
Goodwill 872,737 822,101
Intangible assets, net 534,645 531,522
Other assets 285,302 46,828
Total assets 2,638,692 2,294,805
Current liabilities:    
Trade accounts payable 25,679 33,865
Salaries, wages and related accruals 36,747 61,953
Accrued expenses 14,880 17,886
Contract liabilities 23,069 23,406
Income taxes payable 12,022 13,237
Operating lease liabilities - current 11,199 11,928
Contingent consideration payable 3,500  
Current portion of long-term debt obligations   12,500
Other current liabilities 1,413 1,243
Total current liabilities 128,509 176,018
Deferred income taxes 88,982 98,994
Long-term debt obligations 350,000 243,410
Long-term contingent consideration payable   5,000
Operating lease liabilities 93,766 58,133
Other long-term liabilities 10,919 12,239
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,641,914 and 156,644,212, respectively(1) 1,576 1,566
Additional paid-in capital 721,543 652,467
Retained earnings 1,309,461 1,122,937
Accumulated other comprehensive loss (66,064) (75,200)
Total Bio-Techne's shareholders' equity 1,966,516 1,701,770
Noncontrolling interest   (759)
Total shareholders' equity 1,966,516 1,701,011
Total liabilities and shareholders' equity $ 2,638,692 $ 2,294,805